GlassScriptPhysician profile
Jeffrey B Siegel
NPI 1134187560
$19,229.79
in general payments reported to CMS, 2019-2025
15 companies · $1,702 in 2025
The $1,702 reported for 2025 was more than what 89% of Diagnostic Radiology providers received nationally (typical 2025 total: $112).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2021: $51.92 · 2022: $14.38 · 2023: $265 · 2024: $202 · 2025: $1,702.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,763 · Food and Beverage: $406.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,762.50 |
| Food and Beverage | $405.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merit Medical Systems INC | $18,627.55 | 2019-2025 | |
| Amgen INC. | $165.39 | 2024-2025 | Krystexxa |
| Argon Medical Devices, INC. | $90.17 | 2021-2024 | Clot Management, Cleaner |
| Boston Scientific Corporation | $85.68 | 2019-2023 | |
| Verrica Pharmaceuticals INC. | $48.97 | 2024 | Ycanth |
| Astrazeneca Pharmaceuticals LP | $42.94 | 2023 | Lokelma |
| W. L. Gore & Associates, INC. | $41.49 | 2025 | Viabahn Endoprosthesis With Propaten Bioactive Surface |
| Novo Nordisk INC | $23.53 | 2024 | Ozempic, Rybelsus |
| Abbott Laboratories | $19.94 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $15.97 | 2019 | |
| Angiodynamics, INC. | $15.44 | 2021 | |
| Bard Peripheral Vascular, INC. | $14.38 | 2022 | |
| Alexion Pharmaceuticals, INC. | $14.09 | 2025 | Ultomiris |
| Covidien LP | $12.21 | 2019 | |
| Opko Pharmaceuticals, LLC | $12.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Siegel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.